-

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Outset Medical, Inc. (OM) Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Outset Medical, Inc. (“Outset” or the “Company”) (NASDAQ: OM) securities during the period of August 22, 2022 through August 7, 2024 inclusive (“the Class Period”). Investors have until October 28, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

[Click here to learn more about the class action]

The lawsuit alleges that: (1) Outset's Tablo products were marketed for continuous renal replacement therapy, which is not one of the indications approved by the FDA; (2) that, as a result, Outset Medical was reasonably likely to submit an additional 510(k) application for the Tablo products; (3) that there was a substantial risk that the Company would cease sales of the Tablo products pending FDA approval of additional indications; (4) that Outset Medical lacked the sales team and process to execute on the ramp of Tablo sales; and (5) that, as a result of the foregoing, the Company's revenue growth would be adversely impacted.

If you purchased or otherwise acquired Outset securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this CONTACT FORM, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NASDAQ:OM

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

KD INVESTOR REMINDER: Kyndryl Holdings, Inc. Investors Have Until April 13, 2026 to Seek Lead Plaintiff Role

NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your Kyndryl Holdings, Inc. (“Kyndryl” or the “Company”) (NYSE:KD) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until April 13, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline...

GEMI INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Gemini Space Station, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Gemini Space Station, Inc. (“Gemini” or the “Company”) (NASDAQ:GEMI) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On September 12, 2025, Gemini conducted its initial public offering, selling 15,937,501 shares of Class A co...

QURE INVESTOR REMINDER: uniQure N.V. Investors Have Until April 13, 2026 To Seek Lead Plaintiff Role

NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your uniQure N.V. (“uniQure” or the “Company”) (NASDAQ:QURE) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until April 13, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. The...
Back to Newsroom